Program

The program is under development with additional content to be added shortly.

Day 1

Time Session
8:30 am – 9:00 am Doors open / Breakfast
9:00 am – 9:10 am Brief Introduction and Demonstration Speakers: Ziad Nahas, MD & Elisa Kallioniemi, PhD
9:10 am – 9:25 am What is TMS and TMS Physics Speaker: Elisa Kallioniemi, PhD
9:25 am – 9:45 am Basic Safety Considerations Speaker: Andrew Kozel, PhD
9:45 am – 10:15 am Neuroscientific Applications of TMS Speaker: Elisa Kallioniemi, PhD
10:15 am — 10:45 am Neural Circuit Mapping in Designing Treatment Protocols Speaker: Hamed Ekhtiari, MD, PhD
10:45 am — 12 pm Setting up a TMS Clinic and Integration with other Interventional Neuropsychiatric Services Speaker: Grant Brenner, MD
12 pm – 1:15 pm Lunch / Equipment Exhibits
1:15 pm – 3:30 pm TMS Demonstration Practical Station 1: Beam-F3 Method Practical Station 2: Using Beam Software Practical Station 3: Finding C3 Area
3:30 pm – 3:45 pm Coffee Break / Equipment Exhibits
3:45 pm – 5 pm TMS Demonstration (continued)
5 pm – 6:30 pm Reception / Networking / Equipment Exhibits

Day 2

Time Session
8:30 am – 9:00 am Doors open / Breakfast
9:00 am — 10:30 am Depression Treatment with TMS: History and Importance Speaker: TBD TMS Protocols in Depression • First Generation (rTMS) • Second Generation (Theta Burst) • Third Generation (Accelerated protocols) • SAINT Protocol • Updated TMS Selection Algorithms for TRD • TMS Personalization: New Horizons in Depression Treatment • TMS Protocol in Anxious Depression
10:30 am – 11:00 am Other Neuropsychiatric Applications of TMS TMS in OCD • History and Importance • Targeting Biomarker in OCD: Finding the Exact Target • FDA-Approved Protocol for OCD • CE-Approved Protocol for OCD TMS in Addiction • Transcranial Electrical and Magnetic Stimulation: History and Importance • Targeting Biomarker in Addiction: Personalization • Personalized Targeting of the Frontopolar Area • Network Target Model • FDA and CE Approvals • INTAM Network: Global Collaboration Additional Topics • TMS in Catatonia • TMS in Bipolar Disorder: Mood Stabilization • Target Biomarker in Catatonia • Catatonia and TMS: Restoring Connection to Reality • Other Potentially Clinically Relevant rTMS Protocols Pharmacotherapy and TMS • Psychostimulants • Benzodiazepines • Nicotine / Opioids • Other Medication • D-cycloserine
11:00 am — 11:20 am Mechanisms of Action Speaker: Ziad Nahas, MD
11:20 am — 11:40 am Imaging and TMS Speaker: TBD
11:40 am — 12:00 pm Future Clinical Practice and Research Speaker: TBD
12 pm – 1:30 pm Lunch / Equipment Exhibits
1:30 pm – 4:40 pm TMS Demonstration Practical Station 1: Motor Threshold Assessment Tool Practical Station 2: Adaptive PEST (free tool for TMS researchers and practitioners) Practical Station 3: Neuronavigation & Circuit-based Therapeutics
4:45 pm – 5:30 pm Certification test Faculty: Ziad Nahas, MD & Elisa Kallioniemi, PhD

Disclaimer:

  1. This course alone DOES NOT provide participants with the full expertise to conduct TMS studies. Every participant who is interested in pursuing TMS research is encouraged to contact one of many TMS laboratories for more in-depth training and observership.
  2. It is particularly important that any laboratory using rTMS have a plan to manage seizures. Until the safety of any specific stimulation regimen is firmly established, this should include the presence of medical personnel and the maintenance of emergency equipment and medication close by. The management of seizures is beyond the scope of this course. However, with provoked seizures in otherwise healthy individuals, treatment should consist primarily of getting the patient onto his/her side on a flat surface away from sharp edges, managing the airway, gaining venous access, and providing oxygen. If a neurologist is not readily available during rTMS administration, an algorithm established for administering antiepileptic medication should be established in consultation with a neurologist, so that these are not used indiscriminately, leading to additional problems.